Today: 29 June 2026
NAB share price jumps as inflation keeps rate bets alive — what to watch next
25 February 2026
2 mins read

NAB share price jumps as inflation keeps rate bets alive — what to watch next

Sydney, Feb 25, 2026, 17:07 AEDT — Market closed.

  • National Australia Bank finished Wednesday 1.5% higher at A$49.10.
  • Australia’s core inflation for January came in above expectations, pushing up the chances for a rate hike in the months ahead.
  • Attention shifts to the RBA’s comments expected late Wednesday, with NAB’s May results and dividend schedule also on the radar.

National Australia Bank Ltd finished up 1.5%, settling at A$49.10 after moving in a range from A$48.33 to A$49.12.

Investors responded to a hotter-than-expected January inflation print out of Australia, prompting traders to ramp up bets the Reserve Bank of Australia could hike rates again by May. That’s significant for banks, given their sensitivity to shifts in the rate outlook—it shapes loan pricing, funding expenses and credit appetite.

The consumer price index (CPI) tracks household inflation across the country, while traders keep a close eye on the “trimmed mean” — that’s the version that strips out the sharpest price moves to highlight underlying trends. HSBC chief economist Paul Bloxham pointed out the latest monthly CPI “surprised the market modestly to the upside”, though he emphasized the RBA remains openly skeptical, saying it has “not much faith” in the monthly figure for now. ABC News

Bloxham maintains his main scenario is for the RBA to hike rates in Q3 2026, but he’s not ruling out the chance it happens sooner. Over at Westpac, senior economist Justin Smirk pointed to rents as the major variable, calling attention to his team’s focus: “closely watching rents” for any shift in momentum. ABC News

NAB holders are weighing if higher rates can keep boosting sector earnings, or if they’ll start hurting, as loan growth slows and bad debts creep up. With bank shares already looking pricey after their climb, that trade-off is front and center.

Macquarie and Morgan Stanley analysts are signaling that the big four banks might not deliver the outsized returns investors have enjoyed recently. Price-to-earnings ratios sit near their highest levels in years, and a tighter RBA could trigger sector de-ratings, they say. Both brokers favor NAB, according to the note, but warn that valuations across the banks look fragile if rate expectations climb further.

Here’s the risk: a faster-than-expected economic slowdown, and loan losses could jump from their current lows. Investors, in that case, usually mark down bank earnings. Margin pressure can make a comeback fast, too, as competition on deposits ramps up and squeezes the spread between lending and funding costs.

NAB is scheduled to release its half-year results on May 4, according to the bank’s published dates. The interim dividend goes ex on May 7, with payment due July 2.

Traders are bracing for any hints of change from the RBA ahead of the next ASX session. Governor Michele Bullock is set to speak on Wednesday evening, and eyes are already on the bank’s upcoming decision slated for March 17. Australia’s latest inflation data will follow on March 25.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Gains as Strong Earnings Forecasts Boost Stock
    June 29, 2026, 5:49 AM EDT. Neurocrine Biosciences (NBIX) has emerged as a robust biotech performer with strong earnings momentum driven by its flagship treatment INGREZZA, which treats movement disorders. Analysts have sharply raised earnings per share (EPS) estimates for NBIX across upcoming quarters and fiscal years, reflecting increased confidence in the stock. INGREZZA's sales reached $2.86 billion in 2025, up 22% year-over-year, with projected growth continuing in 2026. The company also benefits from growing physician adoption and expanding patient awareness. Rising earnings forecasts, driven by strong operational performance and a broad consensus among analysts, have elevated NBIX to a Zacks Rank #1 (Strong Buy). Investors see Neurocrine's expanding portfolio and pipeline as key to sustaining growth beyond INGREZZA's success.

Latest articles

ServiceNow (NYSE:NOW) stock: $9 billion Friday jump puts contract base back in focus

ServiceNow (NYSE:NOW) stock: $9 billion Friday jump puts contract base back in focus

29 June 2026
ServiceNow (NYSE:NOW) surged 9.85% to $98.34 Friday, adding $9.1 billion in equity value—about 72% of its $12.64 billion Q1 current remaining performance obligations—as software stocks outperformed amid rotation out of AI names; the move comes ahead of a potential near-term bookings catalyst tied to price increases and legacy tier retirements, with short interest at 5.82% of float.
Nvidia holds $47 billion-per-point sway as Nasdaq tries for bounce

Nvidia holds $47 billion-per-point sway as Nasdaq tries for bounce

29 June 2026
Nvidia’s $4.7 trillion market value means every 1% stock move shifts $47 billion, putting massive index risk in focus as AI capex spending faces fresh scrutiny from new BIS data and rising China chip competition, with premarket gains tested by funding and substitution risks.
Apple stock price climbs as Houston Mac mini shift and China vote put tariffs in focus
Previous Story

Apple stock price climbs as Houston Mac mini shift and China vote put tariffs in focus

SanDisk stock rises as CEO flags multi-year data-center deals after Citron short call
Next Story

SanDisk stock rises as CEO flags multi-year data-center deals after Citron short call

Go toTop